| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TOX.2004.12.022 |
| P8608 | Fatcat ID | release_oitot6sp4rbnvptn2id3ovzpuy |
| P698 | PubMed publication ID | 15767024 |
| P5875 | ResearchGate publication ID | 7967660 |
| P2093 | author name string | Jean-Claude Roujeau | |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heterogeneity | Q928498 |
| P304 | page(s) | 123-129 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Toxicology | Q1666328 |
| P1476 | title | Clinical heterogeneity of drug hypersensitivity | |
| P478 | volume | 209 |
| Q93538760 | Q93538760 |
| Q34982901 | 20-Hydroxylation is the CYP-dependent and retinoid-inducible leukotriene B4 inactivation pathway in human and mouse skin cells |
| Q90170819 | A case of recalcitrant acute generalized exanthematous pustulosis with Sjogren's syndrome: Successfully treated with low-dose cyclosporine |
| Q80593355 | A young man with persistent eosinophilia |
| Q42923666 | Acute Generalized Exanthematous Pustulosis: The First Pediatric Case Caused by a Contrast Agent |
| Q38008719 | Acute generalised exanthematous pustulosis |
| Q38689381 | Acute generalized exanthematous pustulosis due to oral use of blue dyes |
| Q34023005 | Acute generalized exanthematous pustulosis: an unusual side effect of meropenem |
| Q41128099 | Acute oromucosal and palmar desquamation: a severe cutaneous adverse reaction to amphotericin and metronidazole |
| Q40280111 | Adverse cutaneous drug reactions among hospitalized patients: five year surveillance |
| Q34594695 | Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection |
| Q60015736 | Allergies and Childhood Acute Lymphoblastic Leukemia: A Case–Control Study and Meta-analysis |
| Q40407581 | An unusual case of DRESS syndrome |
| Q38026153 | Anticonvulsant hypersensitivity syndrome: an update |
| Q92570447 | Antimicrobial Desensitization: A Review of Published Protocols |
| Q46186592 | Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen |
| Q34030565 | Anything Rare is Possible: Letrozole Induced Eczematous Skin Eruption |
| Q38286229 | Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? |
| Q91640338 | Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis |
| Q47254975 | Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis |
| Q87393358 | Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population |
| Q26853305 | Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis |
| Q42227300 | Case 2: Where did you get that DRESS? |
| Q35518811 | Categorization of allergic disorders in the new World Health Organization International Classification of Diseases |
| Q34167916 | Clinical features of fixed drug eruption at a tertiary hospital in Korea |
| Q34336053 | Concurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy |
| Q42176476 | Constructing a classification of hypersensitivity/allergic diseases for ICD-11 by crowdsourcing the allergist community. |
| Q36444480 | Current understanding of delayed anticonvulsant hypersensitivity reactions |
| Q36059568 | Cutaneous side effects of antiosteoporosis treatments |
| Q35030112 | DRESS syndrome: a case report and literature review |
| Q40405160 | Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese |
| Q47569828 | Diagnosing and managing patients with drug hypersensitivity |
| Q26739766 | Dissemination of definitions and concepts of allergic and hypersensitivity conditions |
| Q36021140 | Drug Eruptions: An 8-year Study Including 106 Inpatients at a Dermatology Clinic in Turkey |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q40136218 | Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse |
| Q40459565 | Drug hypersensitivity syndrome caused by minocycline. |
| Q34701492 | Drug hypersensitivity: pharmacogenetics and clinical syndromes |
| Q40259161 | Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate |
| Q36987789 | Drug rash with eosinophilia and systemic symptoms syndrome: sex and the causative agent |
| Q40241303 | Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study |
| Q40141051 | Drug reaction with eosinophilia and systemic symptoms: a clinicopathological study of six cases at a teaching hospital in midwestern Brazil |
| Q44270147 | Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q33441594 | Drug-induced hypersensitivity reaction: A case of simultaneous thyroiditis and fulminant type 1 diabetes |
| Q34708125 | Drug-induced skin, nail and hair disorders |
| Q36471689 | Eosinophilia: secondary, clonal and idiopathic |
| Q64236304 | Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics |
| Q46414139 | Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions |
| Q40317166 | Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect? |
| Q95839917 | Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes |
| Q89155792 | Genetic markers of severe cutaneous adverse reactions |
| Q37650570 | Genetic predisposition of life-threatening antiepileptic-induced skin reactions. |
| Q37700857 | Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method |
| Q57063736 | HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians |
| Q37341208 | HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. |
| Q34172669 | HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans |
| Q35555607 | HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese |
| Q40984481 | HLA-B*1502 in Iranian Children with Anticonvulsant Drugs-Induced Skin Reactions |
| Q51060800 | HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. |
| Q44155333 | HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese |
| Q26773684 | Hepatic manifestations of non-steroidal inflammatory bowel disease therapy |
| Q40649422 | Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression |
| Q39159544 | Identification of MHC Haplotypes Associated with Drug-induced Hypersensitivity Reactions in Cynomolgus Monkeys |
| Q92509274 | Identification of drug-specific public TCR driving severe cutaneous adverse reactions |
| Q26824391 | Idiosyncratic adverse drug reactions: current concepts |
| Q39558242 | Immunologic evaluation of drug allergy |
| Q34609440 | Immunological principles of T-cell-mediated adverse drug reactions in skin |
| Q37697237 | Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies |
| Q46845991 | Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q43809857 | Is drug allergy less prevalent than previously assumed? A 5-year analysis |
| Q37290367 | Lamotrigine-associated rash: to rechallenge or not to rechallenge? |
| Q64053537 | Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome |
| Q59281741 | Mechanisms in cutaneous drug hypersensitivity reactions |
| Q64241597 | Mild cutaneous reactions to drugs |
| Q62129998 | Monitoring non-immediate allergic reactions to iodine contrast media |
| Q35798638 | Nimesulide induced leukocytoclastic vasculitis and hepatitis: a case report. |
| Q42280232 | Non-follicular milky globules-dermoscopy saves the day. |
| Q36654226 | Occupational trichloroethylene exposure as a cause of idiosyncratic generalized skin disorders and accompanying hepatitis similar to drug hypersensitivities. |
| Q49247755 | PSORS1C1 Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese. |
| Q36269106 | Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics |
| Q58799157 | Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population |
| Q37120841 | Pharmacogenetic information derived from analysis of HLA alleles |
| Q37284234 | Pharmacogenomics in clinical practice and drug development |
| Q38503251 | Progression of drug exanthemas to serious drug eruptions: A retrospective review identifying early determinants |
| Q50063459 | Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. |
| Q55154705 | Recent Advances in Severe Cutaneous Adverse Drug Reaction. |
| Q38931289 | Recent advances in the understanding of severe cutaneous adverse reactions |
| Q40843603 | Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans |
| Q38396234 | Role of dermatology in pharmacogenomics: drug-induced skin injury. |
| Q37989857 | Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper |
| Q40437305 | Severe drug rash with eosinophilia and systemic symptoms after treatment with minocycline |
| Q33955626 | Severe skin complications in patients treated with antidepressants: a literature review. |
| Q42455364 | Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases |
| Q41086444 | Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies |
| Q37091877 | Stevens-Johnson syndrome: pathogenesis, diagnosis, and management |
| Q40407350 | Sulfasalazine-induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms). |
| Q37140546 | Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11. |
| Q38968812 | Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. |
| Q40241296 | Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. |
| Q38161484 | T cell responses to drugs and drug metabolites |
| Q38033651 | T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction |
| Q45958696 | TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. |
| Q36766056 | Testing for drug hypersensitivity syndromes |
| Q38258564 | Tests for evaluating non-immediate allergic drug reactions. |
| Q53251394 | The 2nd International Drug Hypersensitivity Meeting 18 - 21 April 2006, The University of Liverpool, Liverpool, UK. |
| Q40382960 | The molecular mechanism of etanercept, an anti-tumour necrosis factor-alpha receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis |
| Q36395744 | The role of T cells in drug reaction |
| Q42148145 | Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? |
| Q38041396 | Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China |
| Q37634345 | Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity |
| Q38829886 | Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study |
| Q84027448 | [Pustular psoriasis] |
| Q82757982 | [Toxic epidermal necrolysis] |
Search more.